| BRSYF Stock | | | USD 8.53 0.00 0.00% |
Director
Dr. Yiftach Roth serves as Chief Scientific Officer at Brainsway Ltd since November 7, 2006. His work experience includes the following roles Director at the Company, Director at Brainsway Inc and Medical Researcher at the Tel Hashomer Medical Technology Institute, Israel since 2018.
| Age | 52 |
| Tenure | 6 years |
| Phone | 972 2 582 4030 |
| Web | https://www.brainsway.com |
Roth holds a BS degree, a MS degree and a Doctorate of Science degree, all from the Tel Aviv University, in association with Tel Hashomer Hospital.
BrainsWay Management Efficiency
The company has return on total asset
(ROA) of
(0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.2021) %, meaning that it generated substantial loss on money invested by shareholders. BrainsWay's management efficiency ratios could be used to measure how well BrainsWay manages its routine affairs as well as how well it operates its assets and liabilities.
BrainsWay has accumulated 754
K in total debt with debt to equity ratio
(D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. BrainsWay has a current ratio of 7.56, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BrainsWay until it has trouble settling it off, either with new capital or with free cash flow. So, BrainsWay's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BrainsWay sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BrainsWay to invest in growth at high rates of return. When we think about BrainsWay's use of debt, we should always consider it together with cash and equity.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people. BrainsWay [BRSYF] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
BrainsWay Leadership Team
Elected by the shareholders, the BrainsWay's board of directors comprises two types of representatives: BrainsWay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BrainsWay. The board's role is to monitor BrainsWay's management team and ensure that shareholders' interests are well served. BrainsWay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BrainsWay's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Menachem Esq, Gen VP | |
| Christopher Jako, Pres CEO | |
| Avner Hagai, Founder and President and Director | |
| Christopher Boyer, VP Marketing | |
| Hadar Levy, VP COO | |
| Yiftach Roth, Founder, Chief Scientist and Director | |
| Moria Ankri, VP RD | |
| Aron Tendler, Chief Officer | |
| Pr Zangen, Member CoFounder | |
| Richard Areglado, VP CFO | |
BrainsWay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BrainsWay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BrainsWay Pink Sheet
When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our
How to Invest in BrainsWay guide.
You can also try the
Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Please note, there is a significant difference between BrainsWay's value and its price as these two are different measures arrived at by different means. Investors typically determine if BrainsWay is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BrainsWay's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.